Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-osteoporosis therapy in patients with Alzheimer's disease and osteoporosis
ChiCTR2100042909Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in Alzheimer's disease (AD) and osteoporosis (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Bone mineral density, Biochemical examination and 6 more. Started Jan 2021; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
Alzheimer's disease (AD)osteoporosis
Beyond the preview
Go deeper on ChiCTR2100042909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042909.